Alpha 2.0
Login Register
» Authors » Arnold Gammaitoni

Arnold Gammaitoni

Explore the profile of Arnold Gammaitoni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 453
Followers 0
Related Specialties
Neurology
Psychiatry
Pharmacology
Top 10 Co-Authors
Paul M Peloso
Hongwei Wang
Bradley Galer
Steven S Smugar
Bradley S Galer
Gail Farfel
Tilman Polster
Milka Pringsheim
Anish Mehta
Brooks Boyd
Published In
Epilepsy Behav
Pain Med
Clin J Pain
BMC Musculoskelet Disord
Pain
Affiliations
Soon will be listed here.
Recent Articles
1.
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program
Guerrini R, Specchio N, Aledo-Serrano A, Pringsheim M, Darra F, Mayer T, et al.
Epilepsia Open . 2022 Jul; 7(4):578-587. PMID: 35801621
Objective: To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6-17, and ≥18 years old, treated in a real-world setting....
2.
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo
Martin P, Maurice T, Gammaitoni A, Farfel G, Boyd B, Galer B
Epilepsy Behav . 2022 Jan; 127:108526. PMID: 35007961
Fenfluramine (N-ethyl-α-methl-3-(trifluoromethyl)phenethylamine) is an anti-seizure medication (ASM) particularly effective in patients with Dravet syndrome, a severe treatment-resistant epileptic encephalopathy. Fenfluramine acts not only as neuronal serotonin (5-HT) releaser but also...
3.
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice
Sullivan J, Perry M, Wheless J, Galer B, Gammaitoni A
Eur J Paediatr Neurol . 2021 Feb; 31:10-14. PMID: 33540241
Objective: Clinical trials typically report antiepileptic drug efficacy by evaluating reduction in monthly convulsive seizure frequency (MCSF) through group response (active versus placebo). Although useful for regulatory purposes, population statistics...
4.
Fenfluramine HCl (Fintepla ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study
Sullivan J, Scheffer I, Lagae L, Nabbout R, Pringsheim M, Talwar D, et al.
Epilepsia . 2020 Oct; 61(11):2396-2404. PMID: 33078386
Objective: Fenfluramine has been shown to provide clinically meaningful and statistically significant reductions in convulsive seizure frequency in children and adolescents (aged 2-18 years) with Dravet syndrome in two randomized,...
5.
Fenfluramine acts as a positive modulator of sigma-1 receptors
Martin P, de Witte P, Maurice T, Gammaitoni A, Farfel G, Galer B
Epilepsy Behav . 2020 Mar; 105:106989. PMID: 32169824
Objective: Adjunctive fenfluramine hydrochloride, classically described as acting pharmacologically through a serotonergic mechanism, has demonstrated a unique and robust clinical response profile with regard to its magnitude, consistency, and durability...
6.
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al.
Lancet . 2019 Dec; 394(10216):2243-2254. PMID: 31862249
Background: Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has been reported to have antiseizure activity in observational studies of...
7.
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects

Boyd B, Smith S, Gammaitoni A, Galer B, Farfel G
Int J Clin Pharmacol Ther . 2018 Oct; 57(1):11-19. PMID: 30336805
Objective: Phase I, open-label, randomized, single-dose, 3-period crossover study assessing pharmacokinetics (PK) and safety of ZX008, a liquid oral formulation of fenfluramine (FFA) under development for adjunctive treatment of Dravet...
8.
The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study
Gammaitoni A, Smith S, Boyd B
Clin Ther . 2018 Jun; 40(8):1338-1346. PMID: 29941151
Purpose: Fenfluramine is being developed as a low-dose adjunctive treatment for seizures in patients with Dravet syndrome and other epileptic encephalopathies, including Lennox-Gastaut syndrome. Most patients with Dravet syndrome receive...
9.
Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey
Campbell J, Whittington M, Kim C, VanderVeen G, Knupp K, Gammaitoni A
Epilepsy Behav . 2018 Feb; 80:152-156. PMID: 29414545
Objective: The objective of this study was to describe and quantify the impact of caring for a child with Dravet syndrome (DS) on caregivers. Methods: We surveyed DS caregivers at...
10.
The direct and indirect costs of Dravet Syndrome
Whittington M, Knupp K, VanderVeen G, Kim C, Gammaitoni A, Campbell J
Epilepsy Behav . 2018 Feb; 80:109-113. PMID: 29414539
Objective: The objective of this study was to estimate the annual direct and indirect costs associated with Dravet Syndrome (DS). Methods: A survey was electronically administered to the caregivers of...